NIH study suggests people with rare diseases face significantly higher health care costs | National Institutes of Health (NIH)
A new, retrospective study of medical and insurance records indicates health care costs for people with a rare disease have been underestimated and are three to five times greater than the costs for people without a rare disease. The study, led by the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS), provides new evidence of the potential impact of rare diseases on public health, suggesting that nationwide medical costs for individuals with rare diseases are on par with those for cancer and heart failure. The study’s results were published Oct. 21 in the Orphanet Journal of Rare Diseases (link is external) . “There needs to be greater public awareness of the large and growing medical footprint of rare diseases in society,” said senior author Anne Pariser, M.D., director of the NCATS Office of Rare Diseases Research. “Only about 10% of rare diseases have an FDA-approved therapy for their treatment. The findings underscore an urgent need for mo
Friday, October 22, 2021 NIH study suggests people with rare diseases face significantly higher health care costs A new, retrospective study of medical and insurance records indicates health care costs for people with a rare disease have been underestimated and are three to five times greater than the costs for people without a rare disease. The study, led by the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS), provides new evidence of the potential impact of rare diseases on public health, suggesting that nationwide medical costs for individuals wi
Explore this link on the map →related reading
- Why don’t we screen healthy people to catch diseases early? | Out-Of-Pocketoutofpocket.health
- Where are all the trillion dollar biotechs?ladanuzhna.xyz
- New Genzyme pill will cost patients $310,250 a year - The Boston Globeweb.archive.org
- Real-World Evaluation of Direct and Indirect Economic Burden Among Endometriosis Patients in the United States - PMCncbi.nlm.nih.gov
- Rare Diseases at FDA | FDAfda.gov
- Managing the Most Expensive Patientshbr.org
- We wish we’d written that: STAT staffers' favorite stories of 2022statnews.com
- The 23andMe Deal - Cremieux Recueilcremieux.xyz
- Discoveries in Health Policy: Journal Club: The Economist: Have Healthcare Costs Stopped Rising (as Share of GDP)discoveriesinhealthpolicy.com
- Natural History Studies Grants Program | FDAfda.gov
- Unmet Needs Index — Biopharma Disease Prioritizationinsights.convoke.bio
- Slow, Costly Clinical Trials Drag Down Biomedical Breakthroughsmanhattan.institute